General Information of Drug (ID: DMDSCQG)

Drug Name
PF-04840082 Drug Info
Indication
Disease Entry ICD 11 Status REF
Osteoporosis FB83.0 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMDSCQG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BHQ880 DMSROM4 Multiple myeloma 2A83 Phase 2 [3]
DKN-01 DMOHT5V Biliary tract cancer 2C17 Phase 2 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dickkopf-related protein 1 (DKK1) TTE3RAC DKK1_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT01293487) Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.. U.S. National Institutes of Health.
2 The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther. 2010 Apr;333(1):2-13.
3 Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009 Jul 9;114(2):371-9.
4 The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. Expert Opin Investig Drugs. 2020 Jul;29(7):639-644.